Lamotrigine and the risk of fulminant hepatic failure

The Lancet

Volumn 371, Issue 9613, 2008, Pages 649-650

  Shawcross, Debbie ^a   Auzinger, Georg ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GANCICLOVIR; LAMOTRIGINE; VALPROIC ACID; VIRUS DNA;

CLINICAL FEATURE; CYTOMEGALOVIRUS; DISEASE COURSE; DISEASE SEVERITY; DRESS SYNDROME; DRUG EXPOSURE; HUMAN; LETTER; LIVER DYSFUNCTION; LIVER FAILURE; MEDICAL INFORMATION; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 39449108040     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)60300-1     Document Type: Letter

References (5)

1. Iniesta I. Lamotrigine and the risk of fulminant hepatic failure. Lancet 370 (2007) 2101
2. Shawcross D., Knighton S., Bernal W., Sizer E., and Auzinger G. Old versus new antiepileptic drugs: the SANAD study. Lancet 370 (2007) 314-315
3. Marson A., Al Kharusi A., Alwaidh M., et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet 369 (2007) 1000-1015
4. Zaccara G., Franciotta D., and Perucca E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia 48 (2007) 1223-1244
5. Aihara M., Sugita Y., Takahashi S., et al. Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus. Br J Dermatol 144 (2001) 1231-1234